Six-minute walk test: Prognostic value and effects of nebivolol versus placebo in elderly patients with heart failure from the SENIORS trial

Marcelo C. Shibata, Jordan Curl-Roper, Dirk J. van Veldhuisen, Michael Roughton, Andrew J. S. Coats, Marcus Flather

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
4 Downloads (Pure)


Background: There is limited information about the 6-min walk test (6MWT) in elderly patients with heart failure. We evaluated 6MWT and the effect of nebivolol on 6MWT from the SENIORS trial. Methods and results: The SENIORS trial evaluated nebivolol versus placebo on death and hospitalisation in patients aged ≥ 70 years with heart failure. A total of 1982 patients undertook a 6MWT at baseline and 1716 patients at 6 months. Patients were divided into tertiles (≤ 200 m, 201 to ≤ 300 m and > 300 m) and to change in distance walked between baseline and 6 months (< 0 m, 0 to < 30 m and ≥ 30 m). The primary outcome was all-cause mortality and cardiovascular hospital admission. Secondary endpoint was all-cause mortality. Baseline walk distance of ≤ 200 m incurred a greater risk of the primary and secondary outcomes (HR 1.41, CI 95% 1.17–1.69, p < 0.001) and (HR 1.37, CI 95% 1.05–1.78, p = 0.019). A decline in walk distance over 6 months was associated with increased risk of clinical events. Nebivolol had no influence on change in walk distance over 6 months. Conclusions: The 6MWT has prognostic utility in elderly patients. Those who walked less than 200 m were at highest risk. Nebivolol had no effect on 6MWT.
Original languageEnglish
Pages (from-to)1193–1201
Number of pages9
JournalClinical Research in Cardiology
Issue number8
Early online date2 Nov 2020
Publication statusPublished - Aug 2021


  • Elderly
  • Heart failure
  • Prognosis
  • Six-minute walk test

Cite this